SlideShare a Scribd company logo
MerckMillipore.com
The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
André Kiesewetter, Anja Heinen-Kreuzig, Andreas Stein, Merck KGaA, Darmstadt, Germany
High-capacity capture of a recom-
binant growth factor directly from
refold solution using salt tolerant
cation exchange chromatography
© 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, Millipore, the vibrant M and Eshmuno are trademarks of Merck
KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is
available via publicly accessible resources.
Introduction
Growth factors, a class of molecules with eminent therapeutic
potential, are commonly expressed in E. coli as inclusion bodies,
therefore needing homogenization, clarification, solubilization,
and refolding prior to being able to move into traditional down-
stream purification operations. The refold pool presents a
challenge for conventional chromatography media and often
requires significant dilution or buffer exchange in order to
achieve reasonable binding capacities and separations. The
advent of salt tolerant resins offers an opportunity to intensify
these processes by allowing direct connection to the refold pool.
In this work, we evaluated Eshmuno® CPS resin - a new salt
tolerant tentacle resin targeting the purification of biomolecules
from feeds at high salt concentration - for capture of a recom-
binant human growth factor produced in E. coli. As a strong
cation exchanger without hydrophobic groups, the new resin
facilitates easy process development with straightforward
binding and elution conditions.
A cost analysis will compare salt tolerant with conventional
cation exchanger for the growth factor purification.
Results
Dynamic Binding Capacities
DBC was measured for Eshmuno® CPX resin, a standard cation
exchange (CEX) resin, and the new salt tolerant Eshmuno® CPS
resin, both built on Merck's proprietary tentacle technology, as
well as Resin C, a conventional CEX resin not bearing Merck's
tentacles (Figure 1).
Figure 1: Dynamic binding capacities of cation exchange resins
at 10 % breakthrough for rh growth factor at 36 mS/cm.
Purification
Eshmuno® CPX resin
Eshmuno® CPS resin
Figure 2: Eluate profiles.
Eshmuno® CPX resin showed a favourable separation profile for
HCP and rh growth factor: The HCP maximum eluted at the
ascending flank of the growth factor peak. With Eshmuno® CPS
resin the HCP peak was shifted further into the growth factor
peak. Purity (by HPLC) and yield for the indicated pools were
similar for both resins, namely 96 % purity and 93 % yield for
Eshmuno® CPX resin and 95 % purity and 89 % yield for
Eshmuno® CPS resin (Figure 2). The quantitation of HCP is
given in Figure 3.
Figure 3: HCP reduction.
Cost Analysis
Cost and productivity calculations were carried out using a simpli-
fied cost model based on Xenopoulos et al., 2015 (J. Biotechnol.
213, 42-53, A new, integrated, continuous purification process
template for monoclonal antibodies: Process modeling and cost of
goods studies). The calculations compare three scenarios: Scena-
rios 1 and 2 comprise Eshmuno® CPS and Eshmuno® CPX resin,
respectively, with the real case data of the purifications described in
this poster. Scenario 3 employs the virtual case of a conventional
CEX resin with inline diluted feed with a residual low conductivity of
about 5 mS/cm (requires 8 fold dilution) with parameters which are
reasonable from experience. Basis for the calculation is a 2000 L
batch with a titer of 2 g/L and a packed bed height of 20 cm. The
column diameters used reflect the required resin volumes, and do
not take into account the constraint of real existing column sizes.
This focuses on the economics of the operation in general and
allows a direct comparison of the different scenarios. Further
selected input parameters for the calculations are listed in Table 1.
Table 1: Selected input parameters for cost calculation of different
CEX capture scenarios.
Figure 4: Costs and productivities associated with application of
different types of cation exchange resins in rh growth factor
purification.
Use of the standard tentacle cation exchanger compared to the
conventional CEX resin results in a 2.7 fold increase in productivity
and a 2.4 fold reduction of the cost per gram of target produced in
the capture step. Application of the salt tolerant resin gains an addi-
tional 50 % of productivity and a further 1.9 fold cost reduction.
The decisive negative impact in scenario 3 with the conventional
cation exchanger is the large water volume required for feed
dilution. This causes a much longer loading time and in turn the
reduced productivity, and also presents a huge cost driver.
Feed Characteristics
 rec. growth factor after solubilisation and refold in ≈50 mM
Tris, ≈120 mM NaCl, ≈10 mM CaCl2, ≈0.5 M CuSO4, ≈0.3 M
GuaHCl, pH 8.0, 36 mS/cm
 titer: 2 g/L (after ~10X concentration using 5kD cut-off TFF
UF, no diafiltration)
Methods
DBC Measurement
 column dimension: 20 mm L x 8 mm ID, CV = 1.0 mL
 run buffers:
buffer A: 50 mM Tris/HCl + 120 mM NaCl, pH 8.0
buffer B: 50 mM Tris/HCl + 2 M NaCl, pH 8.0
 load: undiluted feed, titer 2 g/L, pH 8.0, 36 mS/cm,
3 min residence time
 wash: 10 CV buffer A at 238.7 cm/h (2 mL/min)
 elution: 10 CV buffer B at 238.7 cm/h
 CIP/re-equilibration:
20 CV 1 M NaOH at 119.4 cm/h (1 mL/min)
15 CV buffer B at 238.7 cm/h
20 CV buffer A at 238.7 cm/h
 fractionation/sampling:
flow-through + wash, fraction size 2 mL
eluate pool, a single 17 mL fraction
 analytics: RP-HPLC (purity, titer)
 evaluation: determination of 10 % breakthrough level of rh
growth factor, calculation of the corresponding dynamic
binding capacity (DBC10%) from load volume
Purification protocol
 column dimension: 200 mm L x 5 mm ID, CV = 3.93 mL
 run buffers: buffer A, buffer B
 load: undiluted feed, titer 2 g/L, pH 8.0, 36 mS/cm,
to 54 – 58 % of DBC10% (due to limited feed),
at 400 cm/h, 3 min residence time
 wash: 10 CV buffer A at 180 cm/h
 gradient elution:
phase 1) 15 – 100 % B in 21 CV at 400 cm/h
phase 2) 2 CV 100 % B at 400 cm/h
 CIP/re-equilibration:
3 CV 1 M NaOH upflow at 120 cm/h
(30 min residence time)
3 CV buffer B upflow at 120 cm/h
10 CV 100 % buffer A at 180 cm/h
 fractionation:
flow-through + wash, fraction size 40 mL
eluate fractions, fraction size 2 mL
 analytics: RP-HPLC (purity, titer), HCP ELISA
 evaluation: purity and yield
Corresponding Author: andreas.stein@merckgroup.com
Lit. No. MK_PS3666EN, Ver. 1.0
Conclusion
 Superior performance of Eshmuno® CPS resin at high salt concentration achieved two times
higher binding capacity compared to standard tentacle cation exchanger.
 A conventional ion exchange resin almost completely failed under these conditions.
 Higher column loading at high salt conditions was associated with some lower selectivity
towards impurity removal.
 The bulk of HCP (90 %) was still removed, though.
 Cost analysis highlights the cost-effectiveness of the new approach of salt tolerant ion
exchangers compared to conventional ion exchange resins which can only be operated at low to
modest salt concentrations.
 Cost per gram of growth factor produced were 4.5 times lower, and productivity was 4 times
greater.
 In addition to the advanced capture step itself, the option of directly connecting capture to
refolding allows intensification of the overall downstream process.
Resin
Loading
capacity
(g/L CV)
Step
yield
(%)
Feed
dilution
factor
Column
diameter
(cm)
Cost of
purified
water
(PW)
($/L)
Buffer
cost
($/L)
Labor
cost
($/h)
Cost of
PW for
dilution
($/batch)
Process
time for
loading
(h)
Eshmuno®
CPS, high
salt
84 89 0 55 1.5 2.0 100 0 2.1
Eshmuno®
CPX, high
salt
40 93 0 79 1.5 2.0 100 0 1.0
Conven-
tional
CEX, plus
inline
dilution
90 93 8 53 1.5 2.0 100 21000 18.0
120
58
4
0
20
40
60
80
100
120
140
Eshmuno®
CPS resin
Eshmuno®
CPX resin
Resin C
(agarose)
DBC(mg/mLsettledresin)
0
20
40
60
80
100
0
5
10
15
20
25
0 10 20 30 40
targetpurity(%)
targettiter(mg/mL)
volume (mL)
Pool
0
200
400
600
0
5
10
15
20
25
0 10 20 30 40
HCP(µg/ml)
µgHCP/mggrowth
factor
targettiter(mg/mL)
volume (mL)
Pool
0
20
40
60
80
100
0
5
10
15
20
25
0 10 20 30 40
targetpurity(%)
targettiter(mg/mL)
volume (mL)
Pool
0
200
400
600
0
5
10
15
20
25
0 10 20 30 40
HCP(µg/ml)
µgHCP/mgrh
growthfactor
targettiter(mg/mL)
volume (mL)
Pool
16
10
0
5
10
15
20
Eshmuno® CPX
resin
Eshmuno® CPS
resin
HCPclearancefactor
4095
(6.2 %)
6002
(9.7 %)
0
20000
40000
60000
load Eshmuno®
CPX
resin
Eshmuno®
CPS
resin
residualHCP(ppm)
16.4
10.9
4.1
1.7
3.1
7.6
0
5
10
15
20
Eshmuno® CPS resin
(high salt feed)
Eshmuno® CPX resin
(high salt feed)
conventional CEX
resin
(inline diluted feed)
Productivity(g/L/h)
Cost($/g)
productivity cost

More Related Content

What's hot

Sucrose low in nanoparticulate impurities for biopharmaceutical formulations
Sucrose low in nanoparticulate impurities for biopharmaceutical formulationsSucrose low in nanoparticulate impurities for biopharmaceutical formulations
Sucrose low in nanoparticulate impurities for biopharmaceutical formulationsMilliporeSigma
 
Inline Flocculation for Harvest and Perfusate Clarification
Inline Flocculation for Harvest and Perfusate ClarificationInline Flocculation for Harvest and Perfusate Clarification
Inline Flocculation for Harvest and Perfusate ClarificationMilliporeSigma
 
Cell Culture Media Filtration – Filter Selection and Sizing
Cell Culture Media Filtration – Filter Selection and SizingCell Culture Media Filtration – Filter Selection and Sizing
Cell Culture Media Filtration – Filter Selection and SizingMilliporeSigma
 
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesHIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesKBI Biopharma
 
Cell Culture Media Filtration – Filter Selection and Sizing
Cell Culture Media Filtration – Filter Selection and SizingCell Culture Media Filtration – Filter Selection and Sizing
Cell Culture Media Filtration – Filter Selection and SizingMilliporeSigma
 
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...MilliporeSigma
 
Development of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsDevelopment of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsNational Institute of Biologics
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...MilliporeSigma
 
Simplification of Fed-Batch Processes Using Modified Amino Acids
Simplification of Fed-Batch Processes Using Modified Amino AcidsSimplification of Fed-Batch Processes Using Modified Amino Acids
Simplification of Fed-Batch Processes Using Modified Amino AcidsMerck Life Sciences
 
Benzonase® endonuclease: use and clearance with a TFF step in a cell culture-...
Benzonase® endonuclease: use and clearance with a TFF step in a cell culture-...Benzonase® endonuclease: use and clearance with a TFF step in a cell culture-...
Benzonase® endonuclease: use and clearance with a TFF step in a cell culture-...Frédéric Sengler
 
Accelerating cell therapy manufacturing through robust process development - ...
Accelerating cell therapy manufacturing through robust process development - ...Accelerating cell therapy manufacturing through robust process development - ...
Accelerating cell therapy manufacturing through robust process development - ...MilliporeSigma
 
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceMerck Life Sciences
 
Innovation in Filter Validation and Technology Transfer
Innovation in Filter Validation and Technology TransferInnovation in Filter Validation and Technology Transfer
Innovation in Filter Validation and Technology TransferMilliporeSigma
 
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...fujifilmdiosynth
 
Cell Line Development: Reducing timelines and increasing titres
Cell Line Development: Reducing timelines and increasing titres Cell Line Development: Reducing timelines and increasing titres
Cell Line Development: Reducing timelines and increasing titres fujifilmdiosynth
 
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...KBI Biopharma
 
Technology Trends in Bioprocessing Purification
Technology Trends in Bioprocessing PurificationTechnology Trends in Bioprocessing Purification
Technology Trends in Bioprocessing PurificationMilliporeSigma
 
Evolution of mAb Downstream Platforms
Evolution of mAb Downstream PlatformsEvolution of mAb Downstream Platforms
Evolution of mAb Downstream PlatformsKBI Biopharma
 
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...KBI Biopharma
 
Custom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Custom Affinity Chromatography for Vaccine Purification: A New PD ParadigmCustom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Custom Affinity Chromatography for Vaccine Purification: A New PD ParadigmMilliporeSigma
 

What's hot (20)

Sucrose low in nanoparticulate impurities for biopharmaceutical formulations
Sucrose low in nanoparticulate impurities for biopharmaceutical formulationsSucrose low in nanoparticulate impurities for biopharmaceutical formulations
Sucrose low in nanoparticulate impurities for biopharmaceutical formulations
 
Inline Flocculation for Harvest and Perfusate Clarification
Inline Flocculation for Harvest and Perfusate ClarificationInline Flocculation for Harvest and Perfusate Clarification
Inline Flocculation for Harvest and Perfusate Clarification
 
Cell Culture Media Filtration – Filter Selection and Sizing
Cell Culture Media Filtration – Filter Selection and SizingCell Culture Media Filtration – Filter Selection and Sizing
Cell Culture Media Filtration – Filter Selection and Sizing
 
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesHIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
 
Cell Culture Media Filtration – Filter Selection and Sizing
Cell Culture Media Filtration – Filter Selection and SizingCell Culture Media Filtration – Filter Selection and Sizing
Cell Culture Media Filtration – Filter Selection and Sizing
 
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
 
Development of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsDevelopment of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applications
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...
 
Simplification of Fed-Batch Processes Using Modified Amino Acids
Simplification of Fed-Batch Processes Using Modified Amino AcidsSimplification of Fed-Batch Processes Using Modified Amino Acids
Simplification of Fed-Batch Processes Using Modified Amino Acids
 
Benzonase® endonuclease: use and clearance with a TFF step in a cell culture-...
Benzonase® endonuclease: use and clearance with a TFF step in a cell culture-...Benzonase® endonuclease: use and clearance with a TFF step in a cell culture-...
Benzonase® endonuclease: use and clearance with a TFF step in a cell culture-...
 
Accelerating cell therapy manufacturing through robust process development - ...
Accelerating cell therapy manufacturing through robust process development - ...Accelerating cell therapy manufacturing through robust process development - ...
Accelerating cell therapy manufacturing through robust process development - ...
 
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
 
Innovation in Filter Validation and Technology Transfer
Innovation in Filter Validation and Technology TransferInnovation in Filter Validation and Technology Transfer
Innovation in Filter Validation and Technology Transfer
 
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
 
Cell Line Development: Reducing timelines and increasing titres
Cell Line Development: Reducing timelines and increasing titres Cell Line Development: Reducing timelines and increasing titres
Cell Line Development: Reducing timelines and increasing titres
 
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
Subvisible Particle Characterization: Why Simply Counting Shadows Leaves You ...
 
Technology Trends in Bioprocessing Purification
Technology Trends in Bioprocessing PurificationTechnology Trends in Bioprocessing Purification
Technology Trends in Bioprocessing Purification
 
Evolution of mAb Downstream Platforms
Evolution of mAb Downstream PlatformsEvolution of mAb Downstream Platforms
Evolution of mAb Downstream Platforms
 
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
 
Custom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Custom Affinity Chromatography for Vaccine Purification: A New PD ParadigmCustom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Custom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
 

Similar to High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Solution Using Salt Tolerant Cation Exchange Chromatography

High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Sol...
High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Sol...High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Sol...
High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Sol...MilliporeSigma
 
Intensified mAb polishing: linking single-pass tangential flow filtration wit...
Intensified mAb polishing: linking single-pass tangential flow filtration wit...Intensified mAb polishing: linking single-pass tangential flow filtration wit...
Intensified mAb polishing: linking single-pass tangential flow filtration wit...Frédéric Sengler
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Merck Life Sciences
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...MilliporeSigma
 
Industrial Applications Of Chromatography Technique
Industrial Applications Of Chromatography TechniqueIndustrial Applications Of Chromatography Technique
Industrial Applications Of Chromatography Techniquerita martin
 
GRC_Poster_2015
GRC_Poster_2015GRC_Poster_2015
GRC_Poster_2015David Gunn
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...MilliporeSigma
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Merck Life Sciences
 
Rapid UHPLC Determination of Common Preservatives in Cosmetic Products
Rapid UHPLC Determination of Common Preservatives in Cosmetic Products Rapid UHPLC Determination of Common Preservatives in Cosmetic Products
Rapid UHPLC Determination of Common Preservatives in Cosmetic Products v2zq
 
New Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode
New Hollow Fiber Membranes for AEX and CEX in Flow-Through ModeNew Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode
New Hollow Fiber Membranes for AEX and CEX in Flow-Through ModeGBX Events
 
11639_10ububhbunubtbinuhubjbubijub061.pdf
11639_10ububhbunubtbinuhubjbubijub061.pdf11639_10ububhbunubtbinuhubjbubijub061.pdf
11639_10ububhbunubtbinuhubjbubijub061.pdfvaibhavbarde287
 
BioInnovation Leader Summit Transforming Process Efficiency
 BioInnovation Leader Summit Transforming Process Efficiency BioInnovation Leader Summit Transforming Process Efficiency
BioInnovation Leader Summit Transforming Process EfficiencyGBX Summits
 
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit TosohDr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit TosohGBX Summits
 
Process Scale Chromatography
Process Scale ChromatographyProcess Scale Chromatography
Process Scale ChromatographyMilliporeSigma
 
Using THGA and Zeeman Background Correction for Blood-Lead Determination in C...
Using THGA and Zeeman Background Correction for Blood-Lead Determination in C...Using THGA and Zeeman Background Correction for Blood-Lead Determination in C...
Using THGA and Zeeman Background Correction for Blood-Lead Determination in C...PerkinElmer, Inc.
 
Anaerobic-Aerobic Treatment of Sewage
Anaerobic-Aerobic Treatment of SewageAnaerobic-Aerobic Treatment of Sewage
Anaerobic-Aerobic Treatment of SewageAmit Christian
 
Waters Oligonucleotide Analysis Solutions
Waters Oligonucleotide Analysis SolutionsWaters Oligonucleotide Analysis Solutions
Waters Oligonucleotide Analysis SolutionsWaters Corporation
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up MilliporeSigma
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-upComplete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-upMerck Life Sciences
 

Similar to High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Solution Using Salt Tolerant Cation Exchange Chromatography (20)

High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Sol...
High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Sol...High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Sol...
High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Sol...
 
Intensified mAb polishing: linking single-pass tangential flow filtration wit...
Intensified mAb polishing: linking single-pass tangential flow filtration wit...Intensified mAb polishing: linking single-pass tangential flow filtration wit...
Intensified mAb polishing: linking single-pass tangential flow filtration wit...
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
 
Industrial Applications Of Chromatography Technique
Industrial Applications Of Chromatography TechniqueIndustrial Applications Of Chromatography Technique
Industrial Applications Of Chromatography Technique
 
GRC_Poster_2015
GRC_Poster_2015GRC_Poster_2015
GRC_Poster_2015
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
 
Rapid UHPLC Determination of Common Preservatives in Cosmetic Products
Rapid UHPLC Determination of Common Preservatives in Cosmetic Products Rapid UHPLC Determination of Common Preservatives in Cosmetic Products
Rapid UHPLC Determination of Common Preservatives in Cosmetic Products
 
New Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode
New Hollow Fiber Membranes for AEX and CEX in Flow-Through ModeNew Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode
New Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode
 
11639_10ububhbunubtbinuhubjbubijub061.pdf
11639_10ububhbunubtbinuhubjbubijub061.pdf11639_10ububhbunubtbinuhubjbubijub061.pdf
11639_10ububhbunubtbinuhubjbubijub061.pdf
 
BioInnovation Leader Summit Transforming Process Efficiency
 BioInnovation Leader Summit Transforming Process Efficiency BioInnovation Leader Summit Transforming Process Efficiency
BioInnovation Leader Summit Transforming Process Efficiency
 
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit TosohDr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
 
Process Scale Chromatography
Process Scale ChromatographyProcess Scale Chromatography
Process Scale Chromatography
 
Process Scale Chromatography
Process Scale ChromatographyProcess Scale Chromatography
Process Scale Chromatography
 
Using THGA and Zeeman Background Correction for Blood-Lead Determination in C...
Using THGA and Zeeman Background Correction for Blood-Lead Determination in C...Using THGA and Zeeman Background Correction for Blood-Lead Determination in C...
Using THGA and Zeeman Background Correction for Blood-Lead Determination in C...
 
Anaerobic-Aerobic Treatment of Sewage
Anaerobic-Aerobic Treatment of SewageAnaerobic-Aerobic Treatment of Sewage
Anaerobic-Aerobic Treatment of Sewage
 
Waters Oligonucleotide Analysis Solutions
Waters Oligonucleotide Analysis SolutionsWaters Oligonucleotide Analysis Solutions
Waters Oligonucleotide Analysis Solutions
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-upComplete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 

More from Merck Life Sciences

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeMerck Life Sciences
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...Merck Life Sciences
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationMerck Life Sciences
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Merck Life Sciences
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...Merck Life Sciences
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Merck Life Sciences
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...Merck Life Sciences
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsMerck Life Sciences
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Merck Life Sciences
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesMerck Life Sciences
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Merck Life Sciences
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...Merck Life Sciences
 
Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Merck Life Sciences
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Merck Life Sciences
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsMerck Life Sciences
 
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Merck Life Sciences
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...Merck Life Sciences
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...Merck Life Sciences
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesMerck Life Sciences
 

More from Merck Life Sciences (20)

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide Alternative
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein Purification
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical Audits
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
 
Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
 
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
 

Recently uploaded

A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisonersAhmed Elmi
 
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur aunty1x1
 
Mental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationMental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationStartupSprouts.in
 
What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...Rick Body
 
Breaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsBreaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsOppositional Defiant Disorder
 
Overcome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxOvercome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxrenewlifehypnosis
 
Jaipur @ℂall @Girls ꧁❤8901183002❤꧂@ℂall @Girls Service Vip Top Model Safe
Jaipur @ℂall @Girls ꧁❤8901183002❤꧂@ℂall @Girls Service Vip Top Model SafeJaipur @ℂall @Girls ꧁❤8901183002❤꧂@ℂall @Girls Service Vip Top Model Safe
Jaipur @ℂall @Girls ꧁❤8901183002❤꧂@ℂall @Girls Service Vip Top Model Safeaunty1x1
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...aunty1x2
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
 
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdfSugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdfDharma Homoeopathy
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
 
Master the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingMaster the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingJoga Yoga Training
 
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxNose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxDr. Rabia Inam Gandapore
 
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...aunty1x1
 
GENERAL PHARMACOLOGY - INTRODUCTION DENTAL.ppt
GENERAL PHARMACOLOGY - INTRODUCTION DENTAL.pptGENERAL PHARMACOLOGY - INTRODUCTION DENTAL.ppt
GENERAL PHARMACOLOGY - INTRODUCTION DENTAL.pptMangaiarkkarasi
 
pathology seminar presentation best ppt by .pptx
pathology seminar presentation best ppt by  .pptxpathology seminar presentation best ppt by  .pptx
pathology seminar presentation best ppt by .pptxAmanuelIbrahim
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
 
Integrated Mother and Neonate Childwood Illness Health Care
Integrated Mother and Neonate Childwood Illness  Health CareIntegrated Mother and Neonate Childwood Illness  Health Care
Integrated Mother and Neonate Childwood Illness Health CareASKatoch1
 
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\DanielOliver74
 
Best Erectile Dysfunction Treatment In Narela
Best Erectile Dysfunction Treatment In NarelaBest Erectile Dysfunction Treatment In Narela
Best Erectile Dysfunction Treatment In NarelaLalClinic
 

Recently uploaded (20)

A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
 
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
 
Mental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationMental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck Presentation
 
What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...
 
Breaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsBreaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder Treatments
 
Overcome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxOvercome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptx
 
Jaipur @ℂall @Girls ꧁❤8901183002❤꧂@ℂall @Girls Service Vip Top Model Safe
Jaipur @ℂall @Girls ꧁❤8901183002❤꧂@ℂall @Girls Service Vip Top Model SafeJaipur @ℂall @Girls ꧁❤8901183002❤꧂@ℂall @Girls Service Vip Top Model Safe
Jaipur @ℂall @Girls ꧁❤8901183002❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
 
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdfSugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
 
Master the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingMaster the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga Training
 
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxNose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
 
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
 
GENERAL PHARMACOLOGY - INTRODUCTION DENTAL.ppt
GENERAL PHARMACOLOGY - INTRODUCTION DENTAL.pptGENERAL PHARMACOLOGY - INTRODUCTION DENTAL.ppt
GENERAL PHARMACOLOGY - INTRODUCTION DENTAL.ppt
 
pathology seminar presentation best ppt by .pptx
pathology seminar presentation best ppt by  .pptxpathology seminar presentation best ppt by  .pptx
pathology seminar presentation best ppt by .pptx
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
 
Integrated Mother and Neonate Childwood Illness Health Care
Integrated Mother and Neonate Childwood Illness  Health CareIntegrated Mother and Neonate Childwood Illness  Health Care
Integrated Mother and Neonate Childwood Illness Health Care
 
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
 
Best Erectile Dysfunction Treatment In Narela
Best Erectile Dysfunction Treatment In NarelaBest Erectile Dysfunction Treatment In Narela
Best Erectile Dysfunction Treatment In Narela
 

High-Capacity Capture of a Recombinant Growth Factor Directly From Refold Solution Using Salt Tolerant Cation Exchange Chromatography

  • 1. MerckMillipore.com The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. André Kiesewetter, Anja Heinen-Kreuzig, Andreas Stein, Merck KGaA, Darmstadt, Germany High-capacity capture of a recom- binant growth factor directly from refold solution using salt tolerant cation exchange chromatography © 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, Millipore, the vibrant M and Eshmuno are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Introduction Growth factors, a class of molecules with eminent therapeutic potential, are commonly expressed in E. coli as inclusion bodies, therefore needing homogenization, clarification, solubilization, and refolding prior to being able to move into traditional down- stream purification operations. The refold pool presents a challenge for conventional chromatography media and often requires significant dilution or buffer exchange in order to achieve reasonable binding capacities and separations. The advent of salt tolerant resins offers an opportunity to intensify these processes by allowing direct connection to the refold pool. In this work, we evaluated Eshmuno® CPS resin - a new salt tolerant tentacle resin targeting the purification of biomolecules from feeds at high salt concentration - for capture of a recom- binant human growth factor produced in E. coli. As a strong cation exchanger without hydrophobic groups, the new resin facilitates easy process development with straightforward binding and elution conditions. A cost analysis will compare salt tolerant with conventional cation exchanger for the growth factor purification. Results Dynamic Binding Capacities DBC was measured for Eshmuno® CPX resin, a standard cation exchange (CEX) resin, and the new salt tolerant Eshmuno® CPS resin, both built on Merck's proprietary tentacle technology, as well as Resin C, a conventional CEX resin not bearing Merck's tentacles (Figure 1). Figure 1: Dynamic binding capacities of cation exchange resins at 10 % breakthrough for rh growth factor at 36 mS/cm. Purification Eshmuno® CPX resin Eshmuno® CPS resin Figure 2: Eluate profiles. Eshmuno® CPX resin showed a favourable separation profile for HCP and rh growth factor: The HCP maximum eluted at the ascending flank of the growth factor peak. With Eshmuno® CPS resin the HCP peak was shifted further into the growth factor peak. Purity (by HPLC) and yield for the indicated pools were similar for both resins, namely 96 % purity and 93 % yield for Eshmuno® CPX resin and 95 % purity and 89 % yield for Eshmuno® CPS resin (Figure 2). The quantitation of HCP is given in Figure 3. Figure 3: HCP reduction. Cost Analysis Cost and productivity calculations were carried out using a simpli- fied cost model based on Xenopoulos et al., 2015 (J. Biotechnol. 213, 42-53, A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studies). The calculations compare three scenarios: Scena- rios 1 and 2 comprise Eshmuno® CPS and Eshmuno® CPX resin, respectively, with the real case data of the purifications described in this poster. Scenario 3 employs the virtual case of a conventional CEX resin with inline diluted feed with a residual low conductivity of about 5 mS/cm (requires 8 fold dilution) with parameters which are reasonable from experience. Basis for the calculation is a 2000 L batch with a titer of 2 g/L and a packed bed height of 20 cm. The column diameters used reflect the required resin volumes, and do not take into account the constraint of real existing column sizes. This focuses on the economics of the operation in general and allows a direct comparison of the different scenarios. Further selected input parameters for the calculations are listed in Table 1. Table 1: Selected input parameters for cost calculation of different CEX capture scenarios. Figure 4: Costs and productivities associated with application of different types of cation exchange resins in rh growth factor purification. Use of the standard tentacle cation exchanger compared to the conventional CEX resin results in a 2.7 fold increase in productivity and a 2.4 fold reduction of the cost per gram of target produced in the capture step. Application of the salt tolerant resin gains an addi- tional 50 % of productivity and a further 1.9 fold cost reduction. The decisive negative impact in scenario 3 with the conventional cation exchanger is the large water volume required for feed dilution. This causes a much longer loading time and in turn the reduced productivity, and also presents a huge cost driver. Feed Characteristics  rec. growth factor after solubilisation and refold in ≈50 mM Tris, ≈120 mM NaCl, ≈10 mM CaCl2, ≈0.5 M CuSO4, ≈0.3 M GuaHCl, pH 8.0, 36 mS/cm  titer: 2 g/L (after ~10X concentration using 5kD cut-off TFF UF, no diafiltration) Methods DBC Measurement  column dimension: 20 mm L x 8 mm ID, CV = 1.0 mL  run buffers: buffer A: 50 mM Tris/HCl + 120 mM NaCl, pH 8.0 buffer B: 50 mM Tris/HCl + 2 M NaCl, pH 8.0  load: undiluted feed, titer 2 g/L, pH 8.0, 36 mS/cm, 3 min residence time  wash: 10 CV buffer A at 238.7 cm/h (2 mL/min)  elution: 10 CV buffer B at 238.7 cm/h  CIP/re-equilibration: 20 CV 1 M NaOH at 119.4 cm/h (1 mL/min) 15 CV buffer B at 238.7 cm/h 20 CV buffer A at 238.7 cm/h  fractionation/sampling: flow-through + wash, fraction size 2 mL eluate pool, a single 17 mL fraction  analytics: RP-HPLC (purity, titer)  evaluation: determination of 10 % breakthrough level of rh growth factor, calculation of the corresponding dynamic binding capacity (DBC10%) from load volume Purification protocol  column dimension: 200 mm L x 5 mm ID, CV = 3.93 mL  run buffers: buffer A, buffer B  load: undiluted feed, titer 2 g/L, pH 8.0, 36 mS/cm, to 54 – 58 % of DBC10% (due to limited feed), at 400 cm/h, 3 min residence time  wash: 10 CV buffer A at 180 cm/h  gradient elution: phase 1) 15 – 100 % B in 21 CV at 400 cm/h phase 2) 2 CV 100 % B at 400 cm/h  CIP/re-equilibration: 3 CV 1 M NaOH upflow at 120 cm/h (30 min residence time) 3 CV buffer B upflow at 120 cm/h 10 CV 100 % buffer A at 180 cm/h  fractionation: flow-through + wash, fraction size 40 mL eluate fractions, fraction size 2 mL  analytics: RP-HPLC (purity, titer), HCP ELISA  evaluation: purity and yield Corresponding Author: andreas.stein@merckgroup.com Lit. No. MK_PS3666EN, Ver. 1.0 Conclusion  Superior performance of Eshmuno® CPS resin at high salt concentration achieved two times higher binding capacity compared to standard tentacle cation exchanger.  A conventional ion exchange resin almost completely failed under these conditions.  Higher column loading at high salt conditions was associated with some lower selectivity towards impurity removal.  The bulk of HCP (90 %) was still removed, though.  Cost analysis highlights the cost-effectiveness of the new approach of salt tolerant ion exchangers compared to conventional ion exchange resins which can only be operated at low to modest salt concentrations.  Cost per gram of growth factor produced were 4.5 times lower, and productivity was 4 times greater.  In addition to the advanced capture step itself, the option of directly connecting capture to refolding allows intensification of the overall downstream process. Resin Loading capacity (g/L CV) Step yield (%) Feed dilution factor Column diameter (cm) Cost of purified water (PW) ($/L) Buffer cost ($/L) Labor cost ($/h) Cost of PW for dilution ($/batch) Process time for loading (h) Eshmuno® CPS, high salt 84 89 0 55 1.5 2.0 100 0 2.1 Eshmuno® CPX, high salt 40 93 0 79 1.5 2.0 100 0 1.0 Conven- tional CEX, plus inline dilution 90 93 8 53 1.5 2.0 100 21000 18.0 120 58 4 0 20 40 60 80 100 120 140 Eshmuno® CPS resin Eshmuno® CPX resin Resin C (agarose) DBC(mg/mLsettledresin) 0 20 40 60 80 100 0 5 10 15 20 25 0 10 20 30 40 targetpurity(%) targettiter(mg/mL) volume (mL) Pool 0 200 400 600 0 5 10 15 20 25 0 10 20 30 40 HCP(µg/ml) µgHCP/mggrowth factor targettiter(mg/mL) volume (mL) Pool 0 20 40 60 80 100 0 5 10 15 20 25 0 10 20 30 40 targetpurity(%) targettiter(mg/mL) volume (mL) Pool 0 200 400 600 0 5 10 15 20 25 0 10 20 30 40 HCP(µg/ml) µgHCP/mgrh growthfactor targettiter(mg/mL) volume (mL) Pool 16 10 0 5 10 15 20 Eshmuno® CPX resin Eshmuno® CPS resin HCPclearancefactor 4095 (6.2 %) 6002 (9.7 %) 0 20000 40000 60000 load Eshmuno® CPX resin Eshmuno® CPS resin residualHCP(ppm) 16.4 10.9 4.1 1.7 3.1 7.6 0 5 10 15 20 Eshmuno® CPS resin (high salt feed) Eshmuno® CPX resin (high salt feed) conventional CEX resin (inline diluted feed) Productivity(g/L/h) Cost($/g) productivity cost